Research Article
MiR-223 Promotes Tumor Progression via Targeting RhoB in Gastric Cancer
Table 1
Clinicopathologic variables and miR-223 expression in 52 GC patients.
| Variable | MiR-223 expression | High (n = 26) | Low (n = 26) | value |
| Age | <65 | 15 | 9 | 0.275 | ≥65 | 11 | 17 | Gender | Male | 20 | 18 | 0.412 | Female | 6 | 8 | Tumor location | Proximal stomach | 4 | 7 | 0.583 | Distal stomach | 14 | 13 | Whole stomach | 8 | 6 | Tumor size (cm) | <5 | 7 | 12 | 0.398 | ≥5 | 19 | 14 | Histology grade | Low | 11 | 8 | 0.217 | Medium | 13 | 15 | High | 2 | 3 | Regional lymph node metastasis | Negative | 11 | 11 | 1.00 | Positive | 15 | 15 | TNM stage | I/II | 6 | 14 | 0.022 | III/IV | 20 | 12 | Live metastasis | Negative | 19 | 26 | 0.004 | Positive | 7 | 0 | Borrmann type | I | 2 | 3 | 0.026 | II | 13 | 7 | III | 6 | 15 | IV | 5 | 1 |
|
|